What would happen if the pace of medical innovation in the U.S. slowed or halted altogether? Imagine the treatments and cures that will never come, for Alzheimer’s, for Parkinson’s, for cancers of all kinds. Imagine also the economic impact: on productivity, on medical costs for people who have conditions without good treatments, on a biopharmaceutical industry that accounts for nearly one out of every five dollars spent on R&D by U.S.
Most Recent Posts
This week, the European Commission hosts the sixth negotiating round of the Transatlantic Trade and Investment Partnership (TTIP) in Brussels. As the Commission notes on its website, the discussions will focus on major issue areas including “trade in goods and services, regulatory issues, government procurement, environmental protection and labor rights, energy and raw materials, and opportunities for small- and medium-sized enterprises (SMEs).” This round, as in the pa
“Over the next 20 years, total annual medical costs for patients with HCV infection are expected to more than double, from $30 billion to over $85 billion.”
For biopharmaceutical companies, patients are our priority. Throughout the research and development process, it is our job to make sure that innovative, new treatments are moving through the pipeline, into the hands of those in need. To achieve this, a number of different issues must be addressed across the U.S. and around the world. This week, the Catalyst touched on a variety of topics that aren’t typically top-of-mind, but represent just a small sample of issues that are important to helping patients live longer, healthier lives.
The debate over the cost and value of innovative medicines has prompted some to make renewed calls for use of a cost-effectiveness or similar standard in the U.S. One example of this was highlighted in a recent column by Ed Silverman at the Wall Street Journal.
Today, Mark Chenoweth of Washington Legal Foundation published a great blog in Forbes (and a similar LTE in San Francisco Chronicle) about upcoming oral arguments for our litigation in Alameda County regarding safe disposal.
Today, the countries participating in the Trans-Pacific Partnership (TPP) agreement begin yet another round of negotiations in Ottawa, Canada. The TPP is a trade deal currently being negotiated between the U.S. and 11 countries in the Pacific Rim region, including Canada and Japan. The agreement is predicted to increase U.S. exports by $125 billion and help transform how business is conducted in the global economy.
Vaccines are a critical medical advancement that has saved countless lives. Through the hard work and dedication of researchers around the world, vaccines have eradicated devastating diseases including smallpox, polio, rubella and the measles, and at least 90 percent eradicated 10 additional infectious diseases. Today, vaccines prevent hepatitis A and B, pneumonia and some cancers and have contributed to the global lifespan increase of six years between 1990 and 2012.
Before we leave to celebrate the holiday weekend, we wanted to talk about the latest happenings in the biopharmaceutical industry and the importance of celebrating patients.
As overall life expectancy continues to grow, so does the number of older Americans, the majority of whom have at least one chronic disease. Chronic diseases not only impact our loved ones living with them, but our families as well and cost the health care system billions of dollars. Prospective medicines currently in the pipeline hold promise to improve health outcomes and provide cost savings.
Collaboration was a central theme of the recent BIO International Convention, which featured panel discussions on AMP-lifying Innovation: NIH, Patient Organizations & Leading Biopharma Firms Mobilize to Tackle Tough Diseases and Playing Nice in the Sandbox: Pre-Competitive Research Consortiums Offer Quicker, Less Expensive Path to Better Medicines.